GSTC (GlobeStar Therapeutics) EV-to-OCF: -3.07 (As of Aug. 10, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is GlobeStar Therapeutics EV-to-OCF?

GlobeStar Therapeutics GSTC -99.00% EV-to-OCF is -3.07 as of Aug. 10, 2026.

EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, GlobeStar Therapeutics's Enterprise Value is $0.45 Mil. GlobeStar Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2024 was $-0.15 Mil. Therefore, GlobeStar Therapeutics's EV-to-OCF for today is -3.07.

The historical rank and industry rank for GlobeStar Therapeutics's EV-to-OCF or its related term are showing as below:

GSTC' s EV-to-OCF Range Over the Past 10 Years
Min: -3.07   Med: 0   Max: 0.83
Current: -2.24

During the past 13 years, the highest EV-to-OCF of GlobeStar Therapeutics was 0.83. The lowest was -3.07. And the median was .

GSTC's EV-to-OCF is not ranked
in the Biotechnology industry.
Industry Median: -3.45 vs GSTC: -2.24

EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2026-08-10), GlobeStar Therapeutics's stock price is $0.0001. GlobeStar Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was $0.000. Therefore, GlobeStar Therapeutics's PE Ratio (TTM) for today is N/A.

GlobeStar Therapeutics  (OTCPK:GSTC) EV-to-OCF Explanation

EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

GlobeStar Therapeutics's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.0001/0.000
=N/A

GlobeStar Therapeutics's share price for today is $0.0001.
GlobeStar Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.

GlobeStar Therapeutics EV-to-OCF Related Terms

GlobeStar Therapeutics EV-to-OCF Historical Data

* Premium members only.

The historical data trend for GlobeStar Therapeutics's EV-to-OCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlobeStar Therapeutics EV-to-OCF Chart

GlobeStar Therapeutics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
EV-to-OCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -21.58 -12.68 -22.15 -8.26 -10.49

GlobeStar Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EV-to-OCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

GSTC vs GBLX, ENDV, CNBX: EV-to-OCF Comparison

For the Biotechnology subindustry, GlobeStar Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GlobeStar Therapeutics EV-to-OCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GlobeStar Therapeutics's EV-to-OCF distribution charts can be found below:

* The bar in red indicates where GlobeStar Therapeutics's EV-to-OCF falls into.


GlobeStar Therapeutics EV-to-OCF Calculation

GlobeStar Therapeutics's EV-to-OCF for today is calculated as:

EV-to-OCF=Enterprise Value (Today)/Cash Flow from Operations (TTM)
=0.454/-0.148
=-3.07

GlobeStar Therapeutics's current Enterprise Value is $0.45 Mil.
GlobeStar Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.15 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EV-to-OCF →
What does a EV-to-OCF of -3.07 mean?
GlobeStar Therapeutics (GSTC) has a EV-to-OCF of -3.07 as of Aug. 10, 2026.
Is GlobeStar Therapeutics' EV-to-OCF too high?
GlobeStar Therapeutics' current EV-to-OCF is -3.07.
How does GlobeStar Therapeutics' EV-to-OCF compare to GBLX and ENDV?
GlobeStar Therapeutics' EV-to-OCF of -3.07 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. GlobeStar Therapeutics's current EV-to-OCF is -3.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlobeStar Therapeutics stock overvalued right now?
GlobeStar Therapeutics (GSTC) has a current EV-to-OCF of -3.07. The current EV-to-OCF is -3.07. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For GlobeStar Therapeutics (GSTC), the current EV-to-OCF is -3.07 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GlobeStar Therapeutics Business Description

Address 719 Jadewin Avenue, Richland, WA, USA, 99352
GlobeStar Therapeutics Corp is a clinical-stage pharmaceutical company introducing a patented formulation of previously approved drugs for the treatment of Multiple Sclerosis. The company is focused on developing therapies for people with serious and life-threatening rare disorders.